World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
60604
World Ranking
7500
National Ranking
290

Overview

Jan G. M. Klijn is affiliated with Erasmus University Rotterdam in the Netherlands. Their academic profile reflects engagement in research activities within this institution.

While specific details on publications, co-authors, and topics of research are not provided, the connection to Erasmus University Rotterdam situates their work within a recognized academic environment. This affiliation may influence their access to research resources and collaborative networks within the Dutch and broader European research contexts.

The absence of listed recent papers suggests limited publicly available bibliographic data or that the scientist's research outputs are not currently indexed in accessible databases. Similarly, there is no detailed information on frequent co-authors or publication venues, indicating that either collaboration networks or publication records are not documented in the provided data.

There are no awards recorded for Jan G. M. Klijn, which might reflect either a focus on work that has yet to be formally recognized or limited documentation of accolades.

The data does not specify main fields of study, subfields, or primary research topics. Therefore, it is not possible to delineate their scientific interests or areas of expertise from the available information.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

    Yixin Wang;Jan G M Klijn;Yi Zhang;Anieta M Sieuwerts

  • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

    M Baum;A U Budzar;J Cuzick;J Forbes

  • Genome-wide association study identifies novel breast cancer susceptibility loci

    Douglas F. Easton;Karen A. Pooley;Alison M. Dunning;Paul D. P. Pharoah

  • Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition

    Mieke Kriege;Cecile T.M. Brekelmans;Carla Boetes;Peter E. Besnard

  • Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations

    Hanne Meijers-Heijboer;Ans van den Ouweland;Jan Klijn;Marijke Wasielewski

  • Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation

    Hanne Meijers-Heijboer;Bert van Geel;Wim L.J. van Putten;Sonja C. Henzen-Logmans

  • Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series,

    Christine Desmedt;Fanny Piette;Sherene Loi;Yixin Wang

  • Subtypes of Breast Cancer Show Preferential Site of Relapse

    Marcel Smid;Yixin Wang;Yi Zhang;Anieta M. Sieuwerts

  • Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.

    Maartje J. Hooning;Akke Botma;Berthe M. P. Aleman;Margreet H. A. Baaijens

  • Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

    Sherene Loi;Benjamin Haibe-Kains;Christine Desmedt;Françoise Lallemand

  • The Clinical Significance of Epidermal Growth Factor Receptor (EGF-R) in Human Breast Cancer: A Review on 5232 Patients

    J. G. M. Klijn;P. M. J. J. Berns;P. I. M. Schmitz;J. A. Foekens

  • Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype

    Sunil R. Lakhani;Jorge S. Reis-Filho;Laura Fulford;Frederique Penault-Llorca

  • Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

    Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck

  • Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial

    Thomas M. Suter;Marion Procter;Dirk J. van Veldhuisen;Michael Muscholl

  • Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study

    Andrea Eisen;Jan Lubinski;Jan Klijn;Pal Moller

  • Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer : a European organization for research and treatment of cancer randomized study with cross-over

    Robert Paridaens;L. Biganzoli;P. Bruning;J.G.M. Klijn

  • BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients

    A. Petrij-Bosch;T. Peelen;M. Van Vliet;R. Van Eijk

  • Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer

    John A. Foekens;Anieta M. Sieuwerts;Marcel Smid;Maxime P. Look

  • Survival and Tumour Characteristics of Breast-Cancer Patients with Germline Mutations of BRCA1

    L. C. Verhoog;C. T. M. Brekelmans;C. Seynaeve;L. M. C. Van Den Bosch

Frequent Co-Authors

John A. Foekens
John A. Foekens Erasmus University Rotterdam
Anieta M. Sieuwerts
Anieta M. Sieuwerts Erasmus University Rotterdam
Caroline Seynaeve
Caroline Seynaeve Erasmus University Rotterdam
Peter Devilee
Peter Devilee Leiden University Medical Center
Steven W. J. Lamberts
Steven W. J. Lamberts Erasmus University Rotterdam
Aad Tibben
Aad Tibben Leiden University
John W.M. Martens
John W.M. Martens Erasmus University Rotterdam
Christi J. van Asperen
Christi J. van Asperen Leiden University Medical Center
Ans M.W. van den Ouweland
Ans M.W. van den Ouweland Erasmus University Rotterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring additional healthcare education options can open doors to rewarding careers beyond the traditional path of studying medicine. Many students opt for online degrees in fields such as nursing, health administration, or medical coding, which offer flexibility and diverse professional opportunities.

If you wish to enter the healthcare field with fewer barriers, there are several easy nursing programs to get into. Some of these do not require exams like the TEAS or HESI, which makes them more accessible—find out more about whether do all nursing schools require the teas.

For those interested in the administrative side of healthcare, there are online health administration programs that can be completed at an accelerated pace. Alternatively, working with healthcare data and insurance may suit some students, and there are resources that detail financial aid for medical billing and coding online classes.

These pathways provide flexible, accessible entry points to the healthcare sector, and may be a great fit for various personal and professional goals.

Best Scientists Citing Jan G. M. Klijn